Immutep (IMMP) vs SCYNEXIS (SCYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immutep (IMMP) has outperformed SCYNEXIS (SCYX) over the past year, gaining 80.8% versus a loss of 56.3%. Over five years, IMMP leads with a -8.5% price change compared with -96.0% for SCYX. SCYNEXIS is the larger company by market cap ($23.7 million vs $22.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | SCYX |
|---|---|---|
| Share price | $3.11 | $2.38 |
| Market cap | $22.92M | $23.69M |
| 1-day change | -9.06% | -8.64% |
| YTD return | +8.74% | -52.93% |
| 1-year return | +80.81% | -56.25% |
| 5-year return | -8.53% | -96.00% |
| EPS (TTM) | $-7.30 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $20.60M |
| Revenue growth (YoY) | — | +449.95% |
| Net income (latest FY) | — | $-8.61M |
| Operating margin | — | -78.03% |
| Net margin | — | -41.79% |
| 52-week high | $70.60 | $9.12 |
| 52-week low | $2.66 | $2.30 |
| Distance from 52-week high | -95.59% | -73.90% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +864.63% | +1426.47% |
| Average volume | 26.07K | 225.27K |
| Shares outstanding | 7.37M | 9.95M |
| Employees | — | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed SCYX by 137.1 percentage points over the past year.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
About SCYNEXIS
SCYX stock →SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
IMMP vs SCYX FAQ
Which is bigger, Immutep or SCYNEXIS?
SCYNEXIS (SCYX) is larger, with a market capitalization of $23.69M compared with $22.92M for Immutep (IMMP).
Which stock has performed better over the past year, IMMP or SCYX?
IMMP returned +80.81% over the past 12 months, compared with -56.25% for SCYX (price return, excluding dividends). Past performance does not predict future results.
Are Immutep and SCYNEXIS in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.